# Cystic fibrosis pathogens persist in the upper respiratory tract following initiation of elexacaftor/tezacaftor/ivacaftor therapy

This repository contains code and subset data files generated and used in analysis in the publication of this manuscript. Please contact Jennifer Bomberger (corresponding author; jbomb@dartmouth.edu) for other data availability.

### File list:
* 20240208_HILLIAM_data_analysis.md: Bash and R code used in the preparation of this manuscript.<br>
* 20240208_HILLIAM_sinus_data.csv: OTU and abundance data table from subjects with pre- and post-ETI samples.<br>
* 20240208_HILLIAM_paired_data.csv:  OTU and abundance data table from subjects with paired sinus and sputum samples.
    + Data in these tables has been processed through QIIME2, phyloseq, and vegan and then filtered to only include samples from relevant subjects.
